Vir Biotechnology Inc (VIR)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 86.84% | 81.92% | 80.31% | 82.41% | 84.48% | 84.59% | 92.94% | 85.38% | 90.74% | 91.67% | 91.29% | 93.27% | 81.53% | 48.07% | -18.23% | -323.84% | -209.99% | -289.07% | -243.03% | -15,245.64% |
| Operating profit margin | -707.97% | -658.31% | -673.27% | -1,014.35% | -1,419.06% | -1,346.32% | -73.52% | -81.59% | 52.71% | 65.67% | 62.25% | 68.78% | 38.71% | -93.44% | -167.71% | -569.60% | -441.64% | -374.86% | -315.30% | -18,553.60% |
| Pretax margin | -715.51% | -685.83% | -682.39% | -976.17% | -1,345.77% | -1,275.28% | -64.30% | -78.24% | 47.72% | 61.30% | 64.05% | 70.82% | 50.58% | -36.66% | -169.70% | -579.10% | -444.06% | -381.12% | -327.02% | -18,889.25% |
| Net profit margin | -713.95% | -678.40% | -669.59% | -957.42% | -1,317.76% | -1,162.41% | -61.33% | -36.18% | 32.64% | 48.25% | 51.33% | 52.50% | 48.63% | -36.86% | -169.84% | -579.45% | -444.14% | -381.47% | -327.31% | -18,903.73% |
The profitability ratios of Vir Biotechnology Inc have shown significant fluctuations over the time periods provided. The Gross Profit Margin started with negative values, indicating losses, but gradually improved, reaching a positive value by December 31, 2021, and continuing to increase favorably through December 31, 2024.
Similarly, the Operating Profit Margin and Pretax Margin started with substantial negative percentages, reflecting losses, but showed a trend towards improvement over time, with periods of positive margins interspersed with negative ones. Notably, there was a drastic improvement in profitability from September 30, 2021, to December 31, 2021.
The Net Profit Margin, which measures net profit relative to revenue, followed a similar pattern, starting with negative values, experiencing losses, and then exhibiting a positive trend towards the end of the data period.
Overall, the profitability ratios of Vir Biotechnology Inc have shown signs of recovery and improvement over time, indicating the company's efforts to enhance operational efficiency and profitability.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -37.00% | -34.54% | -29.09% | -31.86% | -33.79% | -34.03% | -14.00% | -12.16% | 29.73% | 57.69% | 49.90% | 55.18% | 21.53% | -21.43% | -27.76% | -33.79% | -32.32% | -26.75% | -31.60% | -45.93% |
| Return on assets (ROA) | -37.31% | -35.60% | -28.93% | -30.07% | -31.38% | -29.38% | -11.68% | -5.39% | 18.41% | 42.39% | 41.15% | 42.12% | 27.05% | -8.45% | -28.12% | -34.37% | -32.51% | -27.22% | -32.80% | -46.79% |
| Return on total capital | -47.99% | -45.94% | -37.67% | -40.05% | -43.09% | -41.72% | -17.64% | -16.98% | 39.52% | 70.69% | 65.25% | 77.92% | 27.16% | -30.20% | -40.33% | -59.07% | -41.49% | -31.21% | -37.88% | -58.00% |
| Return on equity (ROE) | -45.37% | -42.99% | -33.69% | -34.86% | -38.68% | -35.86% | -14.47% | -7.29% | 24.82% | 53.15% | 55.22% | 60.78% | 36.92% | -11.68% | -40.33% | -59.96% | -41.66% | -31.61% | -39.11% | -58.70% |
Based on the provided data, the profitability ratios of Vir Biotechnology Inc show a mix of performance over the quarters.
1. Operating Return on Assets (Operating ROA): The company's Operating ROA fluctuated significantly during the period under review, starting with negative values and improving gradually to positive values. The highest Operating ROA was observed in September 2022, December 2022, and March 2022. This indicates that the company improved its operational efficiency and profitability in those quarters.
2. Return on Assets (ROA): Similar to Operating ROA, ROA also showed a pattern of improvement over time, starting from negative values and turning positive from December 2021 to June 2022. However, there was a slight dip in profitability in the subsequent quarters. The highest ROA was recorded in June 2022.
3. Return on Total Capital: The Return on Total Capital exhibited a similar trend to ROA, with improvements seen from December 2021 to June 2022. The highest Return on Total Capital was also recorded in March 2022, indicating effective capital utilization during that period.
4. Return on Equity (ROE): The Return on Equity followed a pattern of gradual improvement as well, with the company transitioning from negative to positive values in December 2021 to June 2022. The highest ROE was noted in March 2022, showing enhanced profitability relative to shareholders' equity.
Overall, the profitability ratios of Vir Biotechnology Inc reflect improved performance in the latter part of the period under review, with significant strides made in enhancing operational efficiency, capital utilization, and shareholder value.